newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

  • FDA granted Breakthrough Therapy Designation for bezuclastinib plus sunitinib for imatinib-treated GIST patients
  • Cogent will submit the PEAK NDA under the RTOR program with completion targeted for April 2026
  • PEAK trial results showed a 50% reduction in risk of progression or death (hazard ratio 0.50) compared to sunitinib monotherapy
  • Median progression-free survival was 16.5 months for the combination versus 9.2 months for sunitinib alone
  • The combination demonstrated a well-tolerated safety profile with no new risks observed
  • Full PEAK trial results are scheduled for presentation at a major medical meeting in the first half of 2026
  • A Phase 2 trial for first-line GIST patients with exon 9 mutations is expected to initiate in mid-2026